摘要： 海尔生物业绩快报：2025年营收23.3亿元，同比增长2.0%，海外收入8.4亿元，占比36%。新产 业收入占比48.5%，AI收入15%。公司持续创新，全球化布局深化，盈利能力持续改善。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 创新驱动，新产业贡献近半营收 2 0 2 5年海尔生物旗下四大产业发展势头稳健，以智慧用药、血液技术、实验室解决方案为代表 的新产业势能加速释放，全年新产业收入占比4 8 . 5%，同比增速8 . 8%。 智慧用药产业表现尤为亮眼，增长1 8 . 8%。公司在自动化用药的市场份额已跻身行业前三，出 口体量领跑行业内国产品牌。智慧用药产业持续创新，打造全流程数智化闭环方案，彻底重构 了医院用药场景，实现了多品类药品的灵活抓取与分拣，适配门诊药房、住院药房、静配中心 等医院全场景需求，将药房发药效率提升4 0%以上。公司已累计服务医疗机构突破4 0 0家。海 外市场同样实现突破，公司推动中国原创AI智慧药房出海，在东南亚、中东等区域多点开花。 血液技术产业同样保持双位数增长，增长1 4 . 8%。血液 ...

2月27日晚间，海尔生物（688139.SH）发布了2025年业绩快报，公司去年实现营业收入 23.3亿元 ，同 比增长 2.0% ，第四季度收入同比增速 13.1% 。新产业、新市场和AI引擎动能澎湃，海尔生物展现出强大 发展韧性。 海外发展超预期，营收占比突破 36% 作为深耕全球市场多年的中国生命科学上游企业，海尔生物海外业绩持续增长， 2016 年至 2024 年海外 收入 复合增长率超过 20% 。 2 025 年， 2025 年公司实现海外收入 8.4 亿元 ， 同比增长 17.9% ， 占 公司主营收入比重再创新高达到 36% ， 较 2024 年 提升 5 个百分点 。其中 欧洲区域表现尤为突出，增 长 16.0% ， 亚太区域增长 26.0% ， 美洲区域增长 12.2% ， 非洲区域增长 17.8% 。 凭借高可靠的产品性能与技术领先性，海尔生物已在全球市场赢得广泛信赖，其 超低温、恒温产线 在英 国、意大利、澳大利亚等 6 个国家 占据市场第一份额。 这一市场地位的背后，是 技术的 有力支撑 —— 公司 自主研发的 Eco-Drive 超绿技术 将效能较行业目前最高能效水平提升 30% ...

与此同时，公司全球化布局正从单纯的硬件输出向解决方案输出升级。在意大利，公司为费拉拉医院定制U-blood智能血 液管理系统，让中国智慧用血方案提升医院管理效能与安全性，减少血液浪费；在英国，公司为玛丽女王大学在24小时内提供 定制化的实验室服务方案，成功容纳64台生物安全柜，以高效可靠的交付能力赢得客户信赖。 这些成果得益于公司深化"一国一策"本土化战略，在地化运营团队已覆盖英国、新加坡、阿联酋、法国等18个国家，当地 化产品认证达400余项。值得关注的是，由于在地化运营团队投入增加，公司在提高运营效率的同时也带来成本阶段性上升， 但这也为全球化服务的响应速度和交付质量提供了坚实保障。 营收占比突破36% 深耕生命科学领域上游的企业，海尔生物海外市场持续增长，2016年至2024年海外收入复合增长率超过20%。2025年， 2025年公司实现海外收入8.4亿元，同比增长17.9%，占公司主营收入比重再创新高达到36%，较2024年提升5个百分点。其中欧 洲区域表现尤为突出，该区域收入同比增长16.0%，亚太区域收入同比增长26.0%，美洲区域收入同比增长12.2%，非洲区域收 入同比增长17.8%。 凭借高 ...

格隆汇2月27日丨海尔生物(688139.SH)公布2025年年度业绩快报，2025年公司实现营业收入23.3亿元， 同比增长2.0%，在2024年增长转正的基础上继续提速。第四季度收入同比增速13.1%，内生增长动能持 续强化。2025年公司实现海外收入8.4亿元，同比增长17.9%，占公司主营收入比重再创新高达到36%， 较2024年提升5个百分点；其中欧洲区域增长16.0%，亚太区域增长26.0%，美洲区域增长12.2%，非洲 区域增长17.8%。2025年公司实现国内收入14.7亿元，同比下滑5.5%，自第三季度起环比向好，第四季 度同比增长14.5%，通过拓动销、扩渠道和新模式的持续突破，恢复态势逐渐展现。 报告期内公司毛利率46.8%，主要系子公司新建工厂产能爬坡对制造费用产生扰动所致，随着新产能逐 步释放，第四季度毛利率环比提升约0.7个百分点。净利端承压还与公司为应对外部环境挑战而持续主 动的中长期战略投入有关，重点聚焦在全球化和创新两个方面：（1）重点发力海外市场建设，支撑各 产业尤其是新产业的发展突破。报告期内公司新搭建日本、巴西等6地在地化运营体系，加强亚太和欧 洲等市场推广。（2）加大 ...

公司继续夯实AI底座，AI+自动化技术体系深度融入样本库、院内用药、细胞培养等应用场景，2025年 公司AI相关收入占公司整体收入比重达15%，较2024年提升2.5个百分点。2025年公司实现归母净利润 2.5亿元，同比下滑31.6%。 格隆汇2月27日丨海尔生物(688139.SH)公布2025年年度业绩快报，2025年公司实现营业收入23.3亿元， 同比增长2.0%，在2024年增长转正的基础上继续提速。第四季度收入同比增速13.1%，内生增长动能持 续强化。2025年公司实现海外收入8.4亿元，同比增长17.9%，占公司主营收入比重再创新高达到36%， 较2024年提升5个百分点；其中欧洲区域增长16.0%，亚太区域增长26.0%，美洲区域增长12.2%，非洲 区域增长17.8%。2025年公司实现国内收入14.7亿元，同比下滑5.5%，自第三季度起环比向好，第四季 度同比增长14.5%，通过拓动销、扩渠道和新模式的持续突破，恢复态势逐渐展现。 报告期内公司毛利率46.8%，主要系子公司新建工厂产能爬坡对制造费用产生扰动所致，随着新产能逐 步释放，第四季度毛利率环比提升约0.7个百分点。净利端承压还与 ...

Group 1: Haier Biomedical - Haier Biomedical showcased multiple technological products and digital solutions aimed at addressing practical needs in research and laboratory settings, including a super-speed centrifuge that achieves speeds of 100,000 RPM, filling a domestic gap in the field [2] - The company introduced a fully enclosed automated cell expansion system that enhances consistency and reproducibility in experiments by automating the cell culture process and ensuring data traceability [2] - Haier's biological sample management solution utilizes NAIT recognition technology for automated management in ultra-low temperature environments, significantly reducing labor costs and improving data accuracy [2] - The company presented energy-efficient products, such as ultra-low temperature storage boxes, which reportedly consume 50% less electricity than traditional models [2][3] - Haier Biomedical's products and solutions are now available in over 160 countries and regions, with a commitment to advancing technology development based on user challenges in real-world applications [3] Group 2: Medtronic - Medtronic announced the full localization of its product line in China, showcasing its "fully localized innovative solutions" at the expo, which includes core products for tumor treatment [5] - The company highlighted its Leksell Gamma Knife Elekta Esprit, which supports millimeter-level precision in radiation therapy, and the Elekta Evo platform that integrates AI imaging technology to enhance operational efficiency [5][6] - Medtronic's Elekta Unity system has treated over 10,000 patients since its introduction in China, covering more than 40 types of tumors and generating over 160 related clinical research papers [5][7] - The company aims to support China's "Healthy China 2030" initiative by promoting high-quality radiation therapy technology [7] Group 3: Fosun Pharma - Fosun Pharma presented various innovative drugs and high-end medical devices at the expo, focusing on improving treatment outcomes and quality of life for patients with diseases such as tumors and neurological disorders [8] - The company introduced the Da Vinci surgical robot and CAR-T cell therapy product Yikaida, which has been included in over 110 health insurance plans, enhancing accessibility for lymphoma patients [9] - Fosun's Marie particle therapy system, approved by the FDA, offers a compact design for rapid deployment in hospitals, improving treatment precision for lung and breast tumors [8][9] - The company is actively promoting the application of artificial intelligence in healthcare, with platforms designed for drug decision-making and clinical trial predictions [10]

Core Insights - The China International Import Expo (CIIE) serves as a significant platform for showcasing innovation and collaboration, with Haier Biomedical presenting multiple cutting-edge technologies and solutions this year [1][3] Group 1: Breakthrough Technologies and Innovations - Haier Biomedical introduced the first domestic ultra-speed centrifuge capable of exceeding 100,000 RPM, filling a gap in high-end centrifuge equipment in China and positioning the country as the third globally to master this technology [3] - The company also launched a fully automated closed cell expansion system, designed for cell culture and exosome preparation, which enhances efficiency and reduces contamination risks [3] - The AI-driven low-temperature storage management solution, based on original -86°C NAIT recognition technology, streamlines sample management processes, significantly improving operational efficiency for researchers [5] Group 2: Green Development and Sustainability - Haier Biomedical emphasizes green development, showcasing energy-efficient products that save 50% in daily electricity consumption compared to traditional models, equating to an annual saving of 2,843 kWh [6] - The company has established a comprehensive green value chain covering procurement, manufacturing, logistics, and product lifecycle, with 44 product models receiving Energy Star certification [6] - Haier Biomedical's solar-powered vaccine refrigerators and mobile laboratories have been deployed in over 80 countries along the Belt and Road Initiative, contributing to the "Green Silk Road" [6] Group 3: Global Market Expansion - The company has adopted a localized strategy, with products and solutions reaching over 160 countries and benefiting more than 100 million users globally [7][8] - Haier Biomedical's participation in the CIIE highlights its commitment to high-level openness and innovation in the life sciences sector, with a focus on ecological integration and resource efficiency [8]